Mortality Associated With Time in and Out of Buprenorphine Treatment in French Office-Based General Practice: A 7-Year Cohort Study. Dupouy J, Palmaro A, Fatséas M, Auriacombe M, Micallef J, Oustric S, Lapeyre-Mestre M. Ann Fam Med. 2017 Ju…

Impact of a Mandated Change in Buprenorphine Formulation. Graddy R, Rastegar DA. J Addict Med. 2017 Jul 24. doi: 10.1097/ADM.0000000000000341. Abstract https://www.ncbi.nlm.nih.gov/pubmed/28742624

emocha Mobile Health has been awarded funding by NIDA to study and commercialize adherence technology for people with opioid addiction. In partnership with the University of Washington and Boston Medical Center, emocha will assess patients on office…

RBP-6000 BUPRENORPHINE MONTHLY DEPOT DEMONSTRATES EFFICACY, AFETY AND EXPOSURE - RESPONSE RELATIONSHIP IN OPIOID USE DISORDER Susan Learned, Barbara Haight, Céline Laffont, Dayong Li, Paul J. Fudala, Christian Heidbreder, PhD Disclosure: Al…

RBP-6000 INVESTOR EVENT, JUNE 29TH, 2017 http://www.indivior.com/wp-content/uploads/2017/06/CPDD-Presentation-to-Investors.pdf

A study led by investigators in the University of Kentucky Center on Drug and Alcohol Research (CDAR) has demonstrated a weekly injectable formulation of buprenorphine, CAM2038, suppresses symptoms of withdrawal in patients with opioid use disorder…